KainosMed AIDS Treatment, China NDA 'Approved'..."Entering 1 Trillion Won Market"

[Asia Economy Reporter Hyunseok Yoo] InnosMed's AIDS treatment drug has received final approval for new drug sales (NDA) in China through its partner company. It has begun sales in the Chinese AIDS treatment market, which is growing with a market size exceeding 1 trillion KRW.

KainosMed announced on the 28th that its Chinese partner, Jiangsu Aidea Pharmaceuticals, received sales approval for the AIDS treatment drug (ACC007) from the National Medical Products Administration (NMPA) of China.

Jiangsu Aidea developed the AIDS treatment drug (KM023), which KainosMed had developed up to Phase 1 clinical trials, under the substance name ACC007 after acquiring the technology in 2014. It is prescribed together with Tenofovir (TDF) and Lamivudine (3TC). Last year, it successfully completed Phase 3 clinical trials and submitted an application for production drug registration to the Chinese NMPA.

This NDA approval for the AIDS treatment drug demonstrates KainosMed's development capabilities and high technical expertise, and is expected to be a good example of successful market entry through technology transfer.

KainosMed has benefited from steady annual revenue, supporting its new drug development business. Moreover, ACC007 is the first orally administered AIDS treatment drug developed in China, so a high market share is expected after sales commence.

A company official stated, "The AIDS treatment drug developed with KainosMed's technology has succeeded in commercialization in China," adding, "Significant royalty revenue will be generated following Jiangsu Aidea's sales in China."

He added, "The Chinese AIDS treatment market is showing strong growth, and since the Chinese government plans to support markets such as Brazil and South Africa in the future, profits are expected to expand further."

Jiangsu Aidea is also developing ACC008, a single combination tablet consisting of ACC007, Tenofovir (TDF), and Lamivudine (3TC), and in May applied for new drug approval targeting patients with no prior treatment experience to expedite ACC008's commercialization. Separately, Jiangsu Aidea is conducting Phase 3 clinical trials of ACC008 for patients with prior treatment experience, having received approval from the Institutional Review Board (IRB) of Beijing Ditan Hospital, and is smoothly progressing with related clinical research.

Plans are also underway to accelerate market expansion outside China. Recently, KainosMed and Jiangsu Aidea established a joint venture called Kaidea Global Pte. Ltd to enter emerging markets such as India.

This content was produced with the assistance of AI translation services.